COLLEGIUM PHARMACEUTICAL, INCCOLLEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 17.70% | 5.8M | — | 2024-01-19 |
| Eventide Asset Management, LLC | 8.07% | 2.6M | — | 2024-02-14 |
| The Vanguard Group | 7.09% | 2.3M | — | 2024-02-13 |
| Rubric Capital Management | 3.88% | 1.3M | ▼ -4.58pp | 2024-11-13 |
| Principal Global Investors, LLC | — | 1.7M | — | 2024-11-13 |
Insider Transactions
Net 90d: −$2.74M · buys $0 / sells $2.74MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-18 | David Dieter | EVP & General Counsel | Sell (open market) | 14.0K | $34.92 | $488.1K |
| 2026-03-09 | David Dieter | EVP & General Counsel | Sell (open market) | 6.2K | $36.65 | $228.1K |
| 2026-03-03 | Scott Dreyer | EVP & Chief Commercial Officer | Sell (open market) | 46.4K | $40.36 | $1.87M |
| 2026-03-03 | Scott Dreyer | EVP & Chief Commercial Officer | Sell (open market) | 3.6K | $40.99 | $145.9K |
| 2026-02-10 | David Dieter | EVP & General Counsel | Grant | 22.2K | $0.00 | $0 |
| 2026-02-10 | David Dieter | EVP & General Counsel | Grant | 9.0K | $0.00 | $0 |
| 2026-02-10 | Vikram Karnani | President and CEO | Grant | 79.3K | $0.00 | $0 |
| 2026-02-10 | Vikram Karnani | President and CEO | Grant | 32.5K | $0.00 | $0 |
| 2026-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Grant | 14.3K | $0.00 | $0 |
| 2026-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Grant | 22.8K | $0.00 | $0 |
1–10 of 14
Page 1 / 2